Cart (Loading....) | Create Account
Close category search window
 

Interstitial Photodynamic Therapy of Brain Tumors

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

4 Author(s)
Johansson, A. ; Laser Res. Inst., Univ. Clinic Grosshadern, Munich, Germany ; Kreth, F.-W. ; Stummer, W. ; Stepp, H.

Malignant gliomas are associated with poor prognosis. Photodynamic therapy (PDT), relying on light-activated toxicity of a photosensitizer, has been investigated as a means for improving patient survival. This review presents a summary of clinical results obtained with PDT using different photosensitizers for treating brain malignancies. Particular emphasis is on the use of 5-aminolevulinic acid (ALA) induced protoporphyrin IX (PpIX). PpIX is a potent photosensitizer that displays good tumor-selective uptake and characteristic fluorescence. Here, we present clinical data on PpIX biodistribution and PpIX photobleaching kinetics, indicating high tumor selectivity and rapid photobleaching. These data provide the motivation for the use of a dosimetry model aiming at a complete consumption of PpIX during PDT. This dosimetry model, referred to as the advanced photobleaching model, has been implemented for interstitial PDT (iPDT) relying on stereotactic positioning of radial light diffusers within the tumor volume. A summary of preliminary results from our clinical trial on ALA-mediated brain-iPDT is presented. Finally, recent developments of brain-PDT are discussed with respect to their potential to improve treatment efficacy. We have identified individualized dosimetry, the use of multiple photosensitizers and the combination of photosensitizer and immune response modifiers as the most promising strategies for further preclinical and clinical research.

Published in:

Selected Topics in Quantum Electronics, IEEE Journal of  (Volume:16 ,  Issue: 4 )

Date of Publication:

July-Aug. 2010

Need Help?


IEEE Advancing Technology for Humanity About IEEE Xplore | Contact | Help | Terms of Use | Nondiscrimination Policy | Site Map | Privacy & Opting Out of Cookies

A not-for-profit organization, IEEE is the world's largest professional association for the advancement of technology.
© Copyright 2014 IEEE - All rights reserved. Use of this web site signifies your agreement to the terms and conditions.